From: Development and validation of the self-management profile for type 2 diabetes (SMP-T2D)
MEASURE | N (%) or Mean (SD) |
---|---|
STUDY 1 | 147 (100%) |
Gender | |
Male | 88 (59.9%) |
Female | 59 (40.1%) |
Ethnicity | |
Caucasian | 88 (59.9%) |
Black | 24 (16.3%) |
Hispanic | 21 (14.3%) |
Asian | 11 (7.5%) |
Other | 3 (2.0%) |
Age (at enrollment) | 54.6 (10.8) |
Treatment Assignment | |
Sitagliptan | 64 (43.5%) |
Pioglitazone | 44 (29.9%) |
Exenatide QW | 39 (26.5%) |
BMI (kg/m^2) | 33.7 (5.3) |
A1c | 8.5 (1.2) |
DTSQs frequency of perceived hyperglycemia (0–6) | 2.8 (1.7) |
DTSQs frequency of perceived hypoglycemia (0–6) | 0.9 (1.5) |
WHO-5 Well-Being Index total (0–100) | 67.6 (18.1) |
EQ-5D Visual Analog Scale (0–100) | 76.2 (18.4) |
EQ-5D Item 3 – Usual Activities (1–3, higher score = more problems) | 1.2 (0.4) |
IWQOL-Lite total score (0–100) | 82.6 (15.5) |
STUDY 2 | 93 (100%) |
Gender | |
Male | 61 (65.6%) |
Female | 32 (34.4%) |
Ethnicity | |
Caucasian | 76 (81.7%) |
Black | 12 (12.9%) |
Other | 5 (5.4%) |
Age (at enrollment) | 50.8 (10.5) |
Medication (at enrollment) | |
Metformin only | 61 (65.6%) |
Metformin and TZD | 10 (10.8%) |
TZD only | 1 (1.0%) |
None | 21 (22.6) |
Treatment assignment (Exenatide dose) | |
2 mg, once weekly | 22 (23.7%) |
5 mg, once monthly | 22 (23.7%) |
8 mg, once monthly | 26 (28.0%) |
11 mg, once monthly | 23 (24.7%) |
Baseline BMI (kg/m^2) | 34.1 (5.7) |
Baseline A1c | 8.3 (1.1) |
Baseline DTSQs perceived hyperglycemia | 2.8 (1.9) |
Baseline DTSQs perceived hypoglycemia | 1.0 (1.3) |
Change from baseline in BMI (kg/m^2) | −0.4 (5.3)*** |
Change from baseline in A1c | −1.2 (1.2)*** |
Change from baseline in DTSQs perceived hyperglycemia | −1.1 (2.1)*** |
Change from baseline in DTSQs perceived hypoglycemia | 0.2 (1.6) |